drugset / Trial / NCT01908712
Lamazym Aftercare Study FR Designed to Provide Treatment for French Patients
NaSingle-groupOpen-labelTreatment
Summary
The overall objective of this trial is to provide aftercare treatment with Lamazym and to evaluate the safety of repeated Lamzede i.v. treatment of subjects with alpha-Mannosidosis.
Timeline
- Start
- 2013-08
- Primary completion
- 2022-09-30
- Completion
- 2022-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Velmanase Alfa | Protein / enzyme biologic | 1 mg/kg | Intravenous |